Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Provable Security for Physical Cryptography (PSPC)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Computer science and informatics
Countries involved: Austria,Netherlands
Call:  (ERC-2010-StG_20091028, 2010)
Start date: 2010-11-01
End date: 2015-10-31
Duration (months): 60.0
Total project cost (EUR): 1121206.0
EU funding (EUR): 1121206.0
Participants: 2
Project status: CLOSED

Modern cryptographic security definitions do not capture real world adversaries who can attack the algorithm's physical implementation, as they do not take into account so called side-channel attacks where the adversary learns information about the internal state of the cryptosystem during execution, for example by measuring the running time or the power consumption of a smart-card. Current research on side-channels security resembles a cat and mouse game. New attacks are discovered, and then heuristic countermeasures are proposed to prevent this particular new attacks. This is fundamentally different from the "provable security" approach followed by modern cryptography, where one requires that a cryptosystem is proven secure against all adversaries in a broad and well-defined attack scenario. Clearly, this situation is unsatisfactory: what is provable security good for, if ultimately the security of a cryptosystem hinges on some ad-hoc side-channel countermeasure? Despite this, until recently the theory community did not give much attention to this problem as it was believed that side-channels are a practical problem, and theory can only be of limited use to prevent them. But recently results indicate that this view is much too pessimistic. On a high level, the goal of this project is to bring research on side-channels from the realm of engineering and security research to modern cryptography. One aspect of this proposal it to further investigate the framework of leakage-resilience which adapts the methodology of provable security to the physical world. If a cryptosystem is leakage-resilient, then this implies that its implementation is secure against every side-channel attack, making only some mild (basically minimal) assumptions on the underlying hardware.

Keywords: cryptography,provable security,side-channel attacks
European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults (ENS@T-CANCER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,France,Netherlands,Italy,Spain,United Kingdom,Germany,Germany,Netherlands,Italy,France,Australia,Germany
Call:  (FP7-HEALTH-2010-two-stage, 2010)
Start date: 2011-01-01
End date: 2016-06-30
Duration (months): 66.0
Total project cost (EUR): 8137566.52
EU funding (EUR): 5993978.0
Participants: 17
Project status: CLOSED

Among patients with adrenal masses Adrenocortical carcinoma (ACC) and malignant pheochromocytomas (MPH) are found with a low incidence but very unfavorable prognosis. Due to this poor clinical outcome, concomitant hormone dysregulation and limited treatment options the two cancer entities severely impact on affected patients. However, the rarity of the tumors also impedes clinical studies which are affected by fragmentation and low cohort sizes. The European Network for the Study of Adrenal Tumors (ENS@T) has recently implemented a collection of adrenal tumor related databases and defined an associated network of Biological Resource Centers devoted to research on adrenal tumors. The concurrence of recent achievements of this evolving network, the progress in the understanding of molecular mechanisms and increasing availability of specific diagnostic and therapeutic tools for adrenal cancers provides the unique opportunity to achieve unmatched progress in the implementation of both translation and clinical research dedicated to ACC and MPH. Specifically, the newly formed ENS@T-CANCER consortium will address the following topics: 1. Structuring European clinical and translational research through implementation of a virtual research environment, 2. Improving clinical outcome of patients with adrenal cancer by conducting interventional trials carried out by European centers of excellence, 3. Improvement of differential diagnosis and risk stratification of adrenal cancer, 4. Identification and validation of tools for follow-up of patients with adrenal cancer, 5. Identification of novel biomarkers for treatment response. The ultimate aim of the ENS@T-CANCER Consortium is to develop research in the field of adrenal cancers to improve diagnosis and treatment abilities. The Network will allow recruiting sufficient patients in all relevant European centers, to harmonize diagnosis criteria and to use the various technological approaches of a number of laboratories.

Keywords: adrenal cancer,adrenocortical carcinoma,pheochromocytoma,virtual research environment,clinical study,omic technologies,functional imaging,biomarker
Development of novel diagnostic and therapeutic approaches to improve patient outcome in lung and pancreatic tumours (CANCERALIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,United Kingdom,Belgium,United Kingdom,Germany
Call:  (FP7-HEALTH-2010-two-stage, 2010)
Start date: 2011-04-01
End date: 2014-09-30
Duration (months): 42.0
Total project cost (EUR): 4155432.8
EU funding (EUR): 2996808.8
Participants: 7
Project status: CLOSED

Lung and pancreatic cancers still have a mortality rate over 85% at 5 years of diagnosis, a clear demonstration of the actual treatment failure and the need for improved clinical management. This involves better tools for diagnosis, prognosis, and selection of sensitive and resistant patients to current conventional therapies or improved innovative treatments as well as the development of novel therapeutic strategies. The major objective of this proposal is to improve management of patients with either lung or pancreatic tumors by studying the clinical applications of still not investigated metabolic and signalling pathways with the following aims: -development of new tools for early diagnosis -identification of novel tumour markers for early diagnosis and prognosis -prediction of response to conventional treatments -identification of the molecular mechanisms of generation of resistance -development of improved treatments based on the identification of novel molecular targets -design of novel anticancer strategies. -achieve a better understanding of how combinatorial treatments using current standard clinical procedures with novel treatments under development may improve patient outcome. The proposed consortium is composed of four experimental research groups with a profound knowledge on molecular and cellular biology of cancer, and ample experience in the design of targeted and personalized cancer therapies along with translational research, complemented with three clinical groups with an extensive experience in the clinical management of lung and pancreatic cancer patients, guaranteeing a clinical proof-of principle and applicability, integrating basic-clinical European scientific excellence. Furthermore, the consortium has incorporated one company with direct involvement in critical areas that will make feasible to translate to the clinic the results generated in the project.

Keywords: lung,pancreatic tumors,markers,early diagnosis,prediction,response,chemoresistance,improved,treatments,chok,rho gtpases
Systems biology of liver cancer: an integrative genomic-epigenomic approach (MODHEP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,France,United Kingdom,Netherlands,Italy,United Kingdom,United Kingdom,Israel,Japan,Germany,France,Australia
Call:  (FP7-HEALTH-2010-two-stage, 2010)
Start date: 2011-01-01
End date: 2016-06-30
Duration (months): 66.0
Total project cost (EUR): 16861941.56
EU funding (EUR): 11936899.0
Participants: 18
Project status: CLOSED

Cancer is a complex disease involving multiple genetic and epigenetic events occurring, and influencing each other, over a long period of time. Understanding cancer, and ultimately developing effective targeted therapies, will therefore require that mutations and epigenetic alterations be systematically investigated during the multiple stages of disease development, from identifiable pre-neoplastic phases to overt cancer. Until now, no systematic effort has been undertaken to investigate these multiple layers of genome organization and function during cancer development. MODHEP aims at providing a 360° understanding of liver cancer, one of the most common types of tumors and, because of the homogeneity of the hepatic tissue, the most experimentally tractable one. The consortium brings together elite European scientists in the fields of genetics, chromatin regulation, genomics, liver cancer, computational and systems biology. This combination of skills will allow us to investigate and model at unprecedented resolution the chain of events leading from environmental perturbations and the occurrence of driver mutations to preneoplastic disease and cancer. Our experimental plan reflects some grounded assumptions: 1. cancer cannot be modeled without detailed information on the preneoplastic stages of disease; 2. genetic heterogeneity in humans would make systems-level modeling non realistic from a practical point of view. Both of these limitations are bypassed by the use of well-defined mouse models, followed by evaluation of the main conclusions in clinical samples; 3. many early stage driving events in cancer represent epigenetic alterations, which are invisible to classical genetic analysis, and are confounded by secondary and tertiary events in established tumors. Our approach will enable the identification of therapeutically relevant early-stage genetic and epigenetic alterations and the definition of their interplay in tumor development and maintenance.

Keywords: genomics,epigenetics,liver cancer,systems biology,next generation sequencing
New drugs targeting influenza virus polymerase (FLU-PHARM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,France,France,Germany,Germany,Spain,United States,Austria,Austria,Slovakia,Belgium
Call:  (FP7-INFLUENZA-2010, 2010)
Start date: 2010-11-01
End date: 2015-04-30
Duration (months): 54.0
Total project cost (EUR): 8318210.72
EU funding (EUR): 5998757.0
Participants: 12
Project status: CLOSED

The 2009 H1N1 pandemic and the ongoing threat of highly pathogenic H5N1 strains have focused attention worldwide on the urgent need for effective anti-influenza drug options when the public is not protected by vaccination. The need is pressing since several circulating strains are resistant to currently stock-piled anti-neuraminidase drugs. In this project, we will exploit our recent advances in the detailed mechanistic understanding of the structure and function of the viral polymerase, the replication machine of the virus, to develop new drug candidates that inhibit viral replication in infected cells. The polymerase is an excellent drug target as it is highly conserved in all influenza A strains, whether of avian, swine or human origin. The project consortium includes 12 academic and SME partners from 6 European countries chosen for their expertise and complementarity. The focused drug design programme will start with already existing patented small molecule hits against two different polymerase active site targets and use structure-based medicinal chemistry expertise to arrive at optimized leads to enter preclinical studies. The aim is to take one preclinical candidate to phase 1 clinical trials, with contingency plans in place to cover setbacks. In parallel, a world-leading network of European academic labs will continue fundamental research on influenza polymerase atomic structure, cellular function and role in inter-species transmission, which will feed back into the drug design programme with enhanced assays for polymerase inhibitors, improved understanding of how the inhibitors work in the cellular context and potential resistance mechanisms, as well as providing new targets for future anti-influenza drug-design. If successful, the project will provide new opportunities to treat both seasonal and pandemic flu and thus can have an enormous impact on world-wide public health and well-being as well as the competitiveness of the European pharmaceutical sector

Keywords: influenza virus,pandemic,polymerase,drug design,medicinal chemistry,toxicology,phase 1 clinical trial,atomic structure,inter-species transmission
Switchbox: Maintaining health in old age through homeostasis (SWITCHBOX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Netherlands,Germany,Portugal,Hungary
Call:  (FP7-HEALTH-2010-two-stage, 2010)
Start date: 2011-02-01
End date: 2015-07-31
Duration (months): 54.0
Total project cost (EUR): 8556650.3
EU funding (EUR): 5996688.0
Participants: 6
Project status: CLOSED

Healthy aging requires maintenance of homeostatic control of the physiological systems and functions that are integrated by the hypothalamus. Driven by work in previous EU projects (Crescendo/Lifespan) highlighting insulin signalling and the hypothalamic/pituitary/adrenal and thyroid axes in the regulation of aging, SWITCHBOX will examine the flexibility of these neuroendocrine systems in response to environmental challenges in three established human cohorts with variable aging potential. These human cohorts include offspring of exceptionally long-lived siblings and their partners (controls), people with good vs bad cognitive performance or with high vs low cognitive engagement. Maintaining brain function is emphasised as it reflects an individual’s overall well-being, a major goal in aging research, and because age-related brain disorders represent a major socioeconomic burden. To determine the genetic and cellular underpinnings of the findings in humans, hypothesis-based studies in rodents sharing phenotypes with the human cohorts will be carried out. To clarify the role of the brain in the differential regulation of endocrine axes critical for healthy aging, SWITCHBOX will examine the neuroendocrine and metabolic effects of intranasal (humans) and intra-cerebroventricular (rodents) administration of peptides involved in controlling metabolic homeostasis (e.g. insulin, α-MSH). State-of-the-art technology will be used to measure circadian endocrine and metabolic profiles, brain structure and function (fMRI) and cognitive performance, as well as cellular and molecular features. All data will be entered into an already operational ‘open access’ database. The work aims to take key findings from basic research and translate them into clinically relevant concepts. It will benefit from combining expertise of gerontologists, endocrinologists, molecular and cellular neuroscientists and neuropsychologists. SWITCHBOX ultimately aims to develop conceptually new approaches for the prevention and treatment of age-related disorders.

Keywords: insulin sensitivity,stress,cortisol,thyroid,development,programming,epigenetics,mc4r,cognition,lifestyle,sleep
Tools for minimally invasive diagnostics (DIATOOLS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Sweden,France,Czechia,United States,Sweden
Call:  (FP7-HEALTH-2010-two-stage, 2010)
Start date: 2010-11-01
End date: 2014-10-31
Duration (months): 48.0
Total project cost (EUR): 6550538.4
EU funding (EUR): 5000000.0
Participants: 8
Project status: CLOSED

A new generation of molecular tools is becoming available that can digitally record numbers, identities and locations of a broad range of molecular markers for increased diagnostic accuracy. This project will for the first time combine synergistically several groundbreaking technological innovations by the partners, notably padlock and proximity probes with rolling circle amplification for single molecule detection and counting, directed self-assembly of solid phases, and advanced microfluidics and read-out techniques, bringing these from the research lab into integrated instruments useful in routine. This will enable minimally invasive diagnostics, prognostics, and follow-up of treatment of cancers. Blood samples and fine needle aspirates will be subjected to high content, multiplex and multimodal assays of nucleic acids, proteins and interacting complexes thereof in single cells as well as in cell-free bodily fluids. We will use flow cytometry to collect multi-parameter information for large populations of cells, and individual detected molecules will be recorded using a fluorescence activated molecule counter developed by one of the partners. Also, very rare cells and molecules will be targeted through enrichment techniques using novel capturing approaches of unprecedented efficiency. We will apply these diagnostic approaches to characterize biomarkers in solid tumors and in leukemia and lymphoma for minimally invasive diagnostics, monitoring disease progress and selecting optimal therapy, and the assays will be clinically validated in small-scale studies of well-characterized patient samples. This project directly addresses four of the five topics in this call.

Keywords: molecular tool,microfluidics,cancer,biomarker,diagnostics,high-throughput detection
Integrated whole blood acoustophoresis and homogeneous nucleic acid detection cartridge for rapid sepsis diagnostics (ACUSEP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Finland,Sweden,Spain
Call:  (FP7-HEALTH-2010-two-stage, 2010)
Start date: 2010-12-01
End date: 2014-05-31
Duration (months): 42.0
Total project cost (EUR): 3747480.0
EU funding (EUR): 2870410.0
Participants: 5
Project status: CLOSED

The objective of the ACUSEP research project is to develop an integrated, dry-reagent based disposable ready-to-use cartridge enabling rapid analysis of sepsis-causing organisms and eventual identification of antibiotic resistance directly from suspected blood samples. Sepsis causes annually up to 135 000 deaths in Europe and the early diagnosis is the key to improved survival. Identification of the antibiotic resistance is further beneficial to fast initiation of proper antimicrobial treatment. The rapid diagnostics of sepsis and identification of the causative pathogens can be achieved by research utilizing the recent technological advances; combining acoustophoretic collection of the pathogens from whole blood and photoluminescent dual-tag probe-pair detection technology with nucleic acid amplification providing excellent sensitivity and speed needed in acute diagnostics. The consortium is assembled to cover all the key research areas of the project. It consists of academic research organizations with significant technical and scientific experience of acoustophoretic target organism collection and purification, nucleic acid amplification, photoluminescent reporters and multiplexed homogeneous probe detection technologies. The project will proceed in phases, divided to both parallel and serial tasks in collaboration with SME and clinical partners involved, to perform a clinical evaluation of the developed prototype consumable assay cartridge and to initiate further exploitation activities. The specific objective in FP7 HEALTH-2010 addressed to is to “develop detection and analytical tools and technologies for diagnosis, monitoring and prognosis of diseases.

Keywords: sepsis,bacteremia,acoustophoresis,nucleic acid amplification,lanthanides,photoluminescence,time-resolved fluorometry,ready-to-use cartridge
European multidisciplinary ALS network identification to cure motor neuron degeneration (EURO-MOTOR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Belgium,France,France,Germany,Germany,Germany,Ireland,Italy,Italy,Netherlands,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2010-two-stage, 2010)
Start date: 2011-02-01
End date: 2016-01-31
Duration (months): 60.0
Total project cost (EUR): 11939816.2
EU funding (EUR): 8994361.75
Participants: 15
Project status: CLOSED

Amyotrophic Lateral Sclerosis is one of the most devastating diseases in neurology affecting in Europe 50,000 individuals at any time, and causing around 10,000 deaths each year. ALS is characterized by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS affects otherwise healthy people at any time in adulthood. The patient becomes paralyzed and dies as the result of respiratory failure on average 3 years after onset of symptoms. There is no cure for ALS. The only available drug (Riluzole) is marginally effective in extending the lifespan of ALS patients with 3 to 6 months. Despite recent scientific breakthroughs in the discovery of (1) multiple ALS associated genes, (2) evidence for metabolic dysregulation, (3) environmental risk factors, and (4) the protein TDP43 in aggregates of 95% of ALS patients, mechanistic models applicable to patients are still unknown. This shows that ALS can best be tackled through a systems biology approach which can only be achieved in a large integrative effort at the European level. Euro-MOTOR unites a multidisciplinary partnership of world-leading experts of clinicians, basic scientists and bioinformaticians, and is able to exploit excellent infrastructures for patient sampling, -omics platforms, disease modelling and bioinformatics. Euro-MOTOR will integrate large quantitative -omics data sets from new functional models and from patients in two prospective European, population-based inception cohorts. By leveraging on the variation in the multilevel -omics data, Euro-MOTOR aims to detect key genetic drivers of disease susceptibility/progression, while parametric modelling of the causal connections in identified molecular networks will generate a model of disease. Major findings will be validated in a second prospective patient cohort and adequate functional models, resulting in robust targets that pave the way for novel therapeutic interventions for this disabling and fatal disease.

Keywords: systems biology,genetics,proteomics,metabolomics,causal networks,target hubs,quantitative exposome,population-based,amyotrophic lateral sclerosis,devastating fatal disease